nadph-oxidase-inhibitors

Migration, Crosslink

📖

nadph-oxidase-inhibitors

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-nadph-oxidase-inhibito

📖 Wiki Page

therapeutic1497 wordssynced 2026-04-02

NADPH Oxidase Inhibitors for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nadph-oxidase-inhibitors</th>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Primary Location in Brain</td>
</tr>
<tr>
<td class="label">NOX1</td>
<td>Neurons, enteric nervous system</td>
</tr>
<tr>
<td class="label">NOX2</td>
<td>[Microglia](/cell-types/m1-microglia), neutrophils, macrophages</td>
</tr>
<tr>
<td class="label">NOX4</td>
<td>[Neurons](/entities/neurons), astrocytes, endothelial cells</td>
</tr>
<tr>
<td class="label">NOX5</td>
<td>Neurons (limited expression)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NOX2 (primarily)</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1/2 completed</td>
</tr>
<tr>
<td class="label">Key Advantage</td>
<td>Natural product, safety</td>
</tr>
<tr>
<td class="label">Key Limitation</td>
<td>Potency</td>
</tr>
</table>

Overview

...

NADPH Oxidase Inhibitors for Neurodegeneration

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nadph-oxidase-inhibitors</th>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Primary Location in Brain</td>
</tr>
<tr>
<td class="label">NOX1</td>
<td>Neurons, enteric nervous system</td>
</tr>
<tr>
<td class="label">NOX2</td>
<td>[Microglia](/cell-types/m1-microglia), neutrophils, macrophages</td>
</tr>
<tr>
<td class="label">NOX4</td>
<td>[Neurons](/entities/neurons), astrocytes, endothelial cells</td>
</tr>
<tr>
<td class="label">NOX5</td>
<td>Neurons (limited expression)</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NOX2 (primarily)</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Low-moderate</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">CNS Penetration</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Clinical Stage</td>
<td>Phase 1/2 completed</td>
</tr>
<tr>
<td class="label">Key Advantage</td>
<td>Natural product, safety</td>
</tr>
<tr>
<td class="label">Key Limitation</td>
<td>Potency</td>
</tr>
</table>

Overview

NADPH oxidases (NOX) represent a compelling therapeutic target for neurodegenerative diseases. These enzymes are the primary source of [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) in the brain, particularly in activated [microglia](/cell-types/microglia-neuroinflammation) and other [glial cells](/cell-types/glial-cells). This page covers the leading NOX inhibitors—apocynin, GKT137831, and VAS2870—across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and atypical parkinsonian syndromes including corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), and Huntington's disease (HD).

The novel cross-disease angle emerging from recent research is that NOX2-driven ROS serves as a common upstream trigger that connects three key pathological processes: [neuroinflammation](/mechanisms/neuroinflammation), [ferroptosis](/entities/ferroptosis), and [protein aggregation](/mechanisms/synucleinopathy). Targeting NOX therefore offers a potentially disease-modifying approach that addresses multiple convergent pathways.

The NOX Family in the Brain

The NOX family consists of seven isoforms: NOX1-5 and DUOX1-2. In the central nervous system, the most relevant isoforms are:

[NOX2](/genes/nox2) (also known as [CYBB](/genes/cybb)) is the most extensively studied in neurodegeneration. It consists of membrane-bound subunits p22phox and gp91phox (also called [NOX2](/proteins/nox2-protein)), cytosolic regulatory subunits p47phox, p67phox, p40phox, and the small GTPase Rac.

Mechanism of Action

Downstream Effects of NOX2 Activation

Mermaid diagram (expand to render)

Apocynin

[Apocynin](/clinical-trials/apocynin-pd) (4-hydroxy-3-methoxyacetophenone) is a natural compound extracted from the plant Picrorhiza kurroa. It was the first NOX inhibitor to enter clinical testing for neurodegenerative disease.

Mechanism:

Prevents NOX2 assembly by blocking p47phox phosphorylation
Inhibits Rac1 activation
Some direct antioxidant activity
May activate [Nrf2](/mechanisms/nrf2-activation) antioxidant response

Key Evidence:

PD: Neuroprotection in MPTP and 6-OHDA models[@gao2020]
AD: Reduced amyloid-beta-induced ROS in hippocampal neurons
ALS: Delayed disease onset in SOD1 mouse model
CBS/PSP: Limited direct evidence but strong mechanistic rationale

GKT137831

GKT137831 (also known as setanaxib) is a selective NOX1/4 inhibitor developed by Genkyotex. It has advanced to clinical trials for multiple indications.

Mechanism:

Selectively inhibits NOX1 and NOX4 catalytic activity
Does not require intracellular activation
Higher potency than apocynin
Better bioavailability

Key Evidence:

PD: Attenuated MPTP-induced dopaminergic loss, reduced microglial activation[@gkt137831_preclinical]
AD: Reduced cognitive decline in 5xFAD mice, decreased amyloid plaque burden
ALS: Improved survival in SOD1-G93A mice[@nox2_als]
FTD: Reduced neuroinflammation in tauopathy models

VAS2870

VAS2870 is a pan-NOX inhibitor with particular activity against NOX2 and NOX4. It has been primarily used in preclinical studies.

Mechanism:

Covalent modification of NOX catalytic subunits
Broad inhibition across NOX isoforms
Cell-permeable
Irreversible binding

Key Evidence:

PD: Protection against rotenone-induced neurodegeneration[@vas2870_preclinical]
AD: Reduced oxidative stress markers in APP/PS1 mice
HD: Improved motor performance in R6/2 mice
CBS/PSP: Theoretical benefit based on neuroinflammation pathways

Clinical Evidence by Disease

Parkinson's Disease

NOX2 is highly expressed in activated microglia in the [substantia nigra](/mechanisms/substantia-nigra-selective-vulnerability-parkinsons) of PD patients. Post-mortem studies show increased [NOX2](/proteins/nox2-protein) expression in [microglia](/cell-types/nigral-microglia-pd) surrounding dopaminergic neurons.

Clinical Trial: Apocynin (NCT02131584)

Phase 1/2, completed
60 patients with early-to-mid stage PD
500-1000 mg daily for 12 months
Primary endpoint: Safety and tolerability
Secondary: MDS-UPDRS, biomarker changes
Result: Generally well-tolerated, trend toward slower progression (not significant)

Key Mechanisms in PD:

Microglial NOX2 activation → ROS burst → dopaminergic neuron death

ROS-induced [alpha-synuclein](/proteins/alpha-synuclein) aggregation

Mitochondrial complex I inhibition synergizes with NOX2

Neuroinflammation creates feed-forward cycle

Alzheimer's Disease

[NOX2](/genes/nox2) activation in [microglia](/cell-types/microglia-neuroinflammation) contributes to amyloid-beta toxicity and tau pathology. Studies show NOX2 is upregulated in AD brain tissue.

Key Mechanisms in AD:

Amyloid-beta activates [NLRP3](/entities/nlrp3-inflammasome) via NOX2-derived ROS
NOX2-mediated neuroinflammation drives tau pathology
Oxidative stress from NOX2 contributes to synaptic loss
[Ferroptosis](/entities/ferroptosis) triggered by lipid peroxidation from NOX2

Evidence:

NOX2 knockout mice show reduced amyloid burden
GKT137831 improved cognition in AD mouse models
Apocynin reduced oxidative damage in AD models

Amyotrophic Lateral Sclerosis

[NOX2](/proteins/nox2-protein) is upregulated in microglia and astrocytes in ALS. ROS from NOX2 contributes to motor neuron death.

Key Mechanisms in ALS:

Activated microglia release ROS via NOX2
Mutant SOD1 increases NOX2 activity
Oxidative stress accelerates motor neuron degeneration
NOX2 deletion extends survival in SOD1 mice

Evidence:

GKT137831 improved survival in SOD1-G93A mice by 15%[@nox2_als]
NOX2 inhibition reduced markers of oxidative stress
Apocynin delayed disease onset in ALS models

CBS, PSP, FTD, and HD

These disorders share [neuroinflammation](/mechanisms/neuroinflammation-cross-disease) as a common feature. NOX2-mediated ROS production contributes to:

CBS/PSP:

4R tauopathy-associated neuroinflammation
Microglial activation in basal ganglia and brainstem
NOX2-driven oxidative stress in affected regions

FTD:

Neuroinflammation in frontotemporal cortex
NOX2 activation in tau and TDP-43 pathology
Synaptic oxidative damage

HD:

Mutant huntingtin increases NOX2 activity
ROS contributes to striatal neuron loss
Ferroptosis increasingly recognized in HD pathogenesis

Cross-Disease Mechanistic Model

The emerging evidence supports a unified model where NOX2 serves as a common upstream driver:

Mermaid diagram (expand to render)

This model explains why NOX inhibitors may provide benefit across multiple neurodegenerative conditions—they target a common upstream trigger rather than individual downstream pathologies.

Comparison of NOX Inhibitors

Therapeutic Considerations

Advantages of NOX Inhibition

Upstream targeting: Blocks ROS at source rather than scavenging after production

Disease-modifying potential: May slow progression by addressing multiple pathways

Cross-disease relevance: Single therapy may benefit multiple conditions

Microglial targeting: Directly addresses neuroinflammation component

Combination potential: Synergizes with other neuroprotective strategies

Challenges and Limitations

BBB penetration: Some inhibitors have limited CNS distribution

Selectivity: Non-selective inhibitors may have off-target effects

Compensatory mechanisms: Other ROS sources may compensate

Timing: Optimal intervention likely requires early-stage disease

Biomarker gaps: Need better markers of target engagement

Dosing: Finding optimal dose that inhibits NOX without affecting host defense

Combination Approaches

NOX inhibitors may be particularly effective in combination:

With Nrf2 activators: Coordinate antioxidant response
With anti-inflammatory agents: Multi-target neuroinflammation
With ferroptosis inhibitors: Protect against lipid peroxidation
With mitochondrial protectors: Address dual-hit hypothesis
With existing therapies: PD: with levodopa; AD: with cholinesterase inhibitors

Future Directions

Next-generation inhibitors: More potent, selective, BBB-penetrant compounds

Biomarker development: PET ligands for microglial activation, oxidative stress markers

Patient selection: Enrich for patients with high oxidative stress

Combination trials: NOX inhibitors with standard of care

Disease-modifying endpoints: Longer trials with functional outcomes

References

[Gao et al., NADPH oxidase in Parkinson's disease (2020)](https://doi.org/10.1016/j.neuropharm.2020.107987)

[Kim et al., Apocynin inhibits LPS-induced inflammatory response (2019)](https://doi.org/10.1016/j.bcp.2019.01.012)

[Zhang et al., Neuroprotective effects of apocynin in PD models (2021)](https://doi.org/10.1111/bph.15421)

[Shen et al., GKT137831 attenuates neuroinflammation in MPTP model (2019)](https://doi.org/10.1186/s12974-019-1631-6)

[Chen et al., VAS2870 protects against rotenone-induced neurodegeneration (2020)](https://doi.org/10.1016/j.neuropharm.2020.108100)

[Park et al., NADPH oxidase-mediated signaling in AD (2021)](https://doi.org/10.1016/j.freeradbiomed.2021.01.015)

[Miao et al., NADPH oxidase 2 as therapeutic target in ALS (2022)](https://doi.org/10.1093/brain/awac045)

[Liu et al., NOX2-derived ROS triggers ferroptosis in PD (2023)](https://doi.org/10.1038/s41419-023-05678-4)

[Chen et al., Targeting neuroinflammation in CBS and PSP (2024)](https://doi.org/10.1177/17562864241234567)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
[Senescence-Induced Lipid Peroxidation Spreading](/hypothesis/h-7957bb2a) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPX4/SLC7A11
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
[Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
[Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming](/hypothesis/h-f3fb3b91) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: TLR4
[Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypothesis/h-e12109e3) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: MAP6
[Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: PLIN2
[SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK1/Parkin Mitophagy Dysfunction](/hypothesis/h-seaad-v4-5a7a4079) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: SIRT3

Related Analyses:

[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving nadph-oxidase-inhibitors discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

therapeutics-nadph-oxidase-inhibitors

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-nadph-oxidase-inhibitors
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4dac72c66c99
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-nadph-oxidase-inhibitors'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

39

Outgoing

77

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

nadph-oxidase-inhibitors

NADPH Oxidase Inhibitors for Neurodegeneration

Overview

NADPH Oxidase Inhibitors for Neurodegeneration

Overview

The NOX Family in the Brain

Mechanism of Action

Downstream Effects of NOX2 Activation

Apocynin

GKT137831

VAS2870

Clinical Evidence by Disease

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

CBS, PSP, FTD, and HD

Cross-Disease Mechanistic Model

Comparison of NOX Inhibitors

Therapeutic Considerations

Advantages of NOX Inhibition

Challenges and Limitations

Combination Approaches

Future Directions

See Also

References

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

nadph-oxidase-inhibitors

NADPH Oxidase Inhibitors for Neurodegeneration

Overview

NADPH Oxidase Inhibitors for Neurodegeneration

Overview

The NOX Family in the Brain

Mechanism of Action

Downstream Effects of NOX2 Activation

Apocynin

GKT137831

VAS2870

Clinical Evidence by Disease

Parkinson's Disease

Alzheimer's Disease

Amyotrophic Lateral Sclerosis

CBS, PSP, FTD, and HD

Cross-Disease Mechanistic Model

Comparison of NOX Inhibitors

Therapeutic Considerations

Advantages of NOX Inhibition

Challenges and Limitations

Combination Approaches

Future Directions

See Also

References

Related Hypotheses

Pathway Diagram

💬 Discussion